The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system and thus improving the lives of millions of patients worldwide.
EDITOR OF THE MONTH
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital.

Read More
Featured image
New this week :

Going beyond the liver in NAFLD/NASH: hepatologist’s/endocrinologist’s perspective

Featured image

Slide
Featured image
New this week :

Going beyond the liver in NAFLD/NASH: hepatologist’s/endocrinologist’s perspective

Featured image
EDITOR OF THE MONTH


Prof. Dr. Sven Francque obtained his MD at the
University of Antwerp, Belgium, in 1994 and
was subsequently trained in internal medicine
and in gastroenterology and hepatology at the
Antwerp University Hospital.

Read More

Slide

PROF. DR. SVEN FRANCQUE


Editor of the month

Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France.


Featured image
New this week :

Going beyond the liver in NAFLD/NASH: hepatologist’s/endocrinologist’s perspective

Featured image
PROF. DR. SVEN FRANCQUE
Featured image
New this week :

Going beyond the liver in NAFLD/NASH: hepatologist’s/endocrinologist’s perspective

Featured image

UPCOMING EVENTS

e-SPACE Cardio Renal Metabolic 2022
Congress on obesity
ICFL 2022
5th Global NASH Congress
EASL

LATEST ARTICLES

View All

Latest Videos

View All

    Send your message to us

    sign up for our newsletter

    The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide.

    Subscribe to us and get new updates

    prof image
    Prof. Dr. Sven Francque

    2021 has confirmed the rise in the prevalence of nonalcoholic fatty liver disease (NAFLD). NAFLD is part of a multisystem disease and is considered the hepatic manifestation of metabolic syndrome. A proportion of patients with NAFLD develop non-alcoholic steatohepatitis (NASH), with increasing hepatic fibrosis leading eventually to cirrhosis, liver cancer, end-stage liver disease and death. However NASH remains a major unmet medical need and patients with NASH are left with very few management options apart from lifestyle interventions.

    2021 saw some significant progress regarding pharmacological approaches with the positive results of the phase 2b NATIVE trial. This trial featured a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH.

    There is a still a long way before we can close all the gaps in the field of NASH. In 2022, the PanNASH initiative will increase its efforts to contribute to awareness, education and research. We wish you a happy 2022 despite of the current COVID 19 pandemic and look forward to your proactive interaction with the PanNASH platform in 2022.
    Best wishes